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Objective. Chronic kidney disease (CKD) and preeclampsia (PE)may both present with hypertension and proteinuria in pregnancy.
Our objective is to test the possibility of distinguishingCKD fromPEbymeans of uteroplacental flows andmaternal circulating sFlt-
1/PlGF ratio. Design. Prospective analysis. Population. Seventy-six patients (35 CKD, 24 PE, and 17 other hypertensive disorders),
with at least one sFlt-1/PlGF andDoppler evaluation after the 20th gestationalweek.Methods.Maternal sFlt-1-PlGFwere determined
by immunoassays. Abnormal uterine artery Doppler was defined as resistance index ≥ 0.58. Umbilical Doppler was defined with
gestational-age-adjusted Pulsatility Index. Clinical diagnosis was considered as reference. Performance of Doppler study was
assessed by sensitivity analysis; sFlt-1/PlGF cut-off values were determined by ROC curves. Results. The lowest sFlt-1/PlGF ratio
(8.29) was detected in CKD, the highest in PE (317.32) (𝑃 < 0.001). Uteroplacental flows were mostly preserved in CKD patients
in contrast to PE (𝑃 < 0.001). ROC analysis suggested two cut-points: sFlt-1/PlGF ≥ 32.81 (sensitivity 82.93%; specificity 91.43%)
and sFlt-1/PlGF ≥ 78.75 (sensitivity 62.89%, specificity 97.14%). Specificity reached 100% at sFlt-1/PlGF ≥ 142.21 (sensitivity: 48.8%).
Early-preterm delivery was associated with higher sFlt-1/PlGF ratio and abnormal uteroplacental flows relative to late-preterm
and term deliveries. Conclusions. sFlt-1/PlGF ratio and uteroplacental flows significantly correlated with PE or CKD and preterm
delivery.
1. Introduction
Preeclampsia (PE) and chronic kidney disease (CKD) in
pregnancy share several features. Under these broad and
recently changed definitions there are both mildly affected
subjects compatible with term delivery of appropriate for
gestational age babies and stormy, severe diseases that result
in small for gestational age (SGA) babies with relevant
morbidity and mortality [1–4].
CKD has been redefined in the new millennium as any
pathological abnormality or marker of damage, including
abnormalities in blood or urine tests or in imaging studies,
irrespective of kidney function (which is used for classifica-
tion), lasting for at least 3 months [5]. According to these
broad definitions, PE and CKD have a similar prevalence,
being encountered in 3–5% of all pregnancies [1–4, 6].
The commonly held definition of PE states that it is
a reversible condition characterized by hypertension and
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proteinuria, occurring after the 20th week of pregnancy
in previously normotensive, nonproteinuric women [7–10].
More recently, the ACOG guidelines state that PE may
be diagnosed in the absence of proteinuria, when new-
onset hypertension is accompanied by one of the following:
serum creatinine increase, low platelet count or high liver
enzymes, pulmonary edema, or central symptoms [11]. The
kidney is central to these definitions; the broad etiquette of
“superimposed PE” has been used to indicate both placental
dysfunction and worsening of the kidney disease, adding
to the current ambiguity of this term [12]. Regardless of
the definition, proteinuria reflects damage to the glomerular
filtration barrier, mainly reflected by podocyturia, whichmay
be a first sign of permanent renal damage [13, 14].
Since both PE and CKD are characterised by protein-
uria, hypertension, and progressive renal impairment, the
differential diagnosis may be difficult or impossible during
pregnancy, and occasionally also after delivery [15, 16].
Two previous retrospective analyses by our group sug-
gested a role for uteroplacental flows and for two serum
biomarkers, soluble Fms-like tyrosine kinase 1 (sFlt-1) and
Placental Growth Factor (PlGF), in distinguishing between
PE and chronic kidney disease (CKD) in patients with
hypertension and proteinuria during pregnancy [16, 17].
The interest for the uteroplacental flow analysis is linked
to its role not only in the diagnosis, but also in the clinical
management of PE patients; the low precision is counterbal-
anced by the wide availability and simplicity of use [18–20].
The sFlt-1/PlGF ratio is considered one of themost promising
biomarkers for preeclampsia. Its use in clinical practice is still
controversial [21–26]. In fact, some authors objected that sFlt-
1/PlGF ratio best correlated with overt PE, whose diagnosis is
usually self-evident, and that, in the absence of overt PE, the
predictive value for PE development is not precise enough to
be added to the routine clinical work-up [24–29].
The objective of the present prospective study is testing
a different indication for both Doppler study and serum
biomarkers: the possibility to distinguish between CKD and
PE by adding the uteroplacental flow analysis and sFlt-1/PlGF
ratio to the clinical definitions. This is the first prospective
study to combine the sFlt-1/PlGF ratio with uteroplacental
flow for the differential diagnosis of CKD versus PE, taking
into account also other related hypertensive pregnancy dis-
orders.
2. Methods
2.1. Study Population. Thestudywas conducted at theGynae-
cology and Obstetrics Unit of the O.I.R.M-Sant’Anna Hos-
pital, University of Turin (Turin, Italy). The study was per-
formed in adherence to the Declaration of Helsinki. Patients
were recruited and blood samples were collected after obtain-
ing informed consent, in accordance with the ethics guide-
lines of the O.I.R.M-Sant’Anna Hospital Ethics Committee
(approval of the Ethics Committee of O.I.R.M.-Sant’Anna
Hospital number 335; protocol 11551/c28.2; 4/3/2011).
The study consecutively enrolled seventy-six patients
with known CKD (𝑛 = 35) or with a clinical suspicion of PE
(PE 𝑛 = 24; other hypertensive disorders 𝑛 = 17) who had the
following characteristics in the period January–December
2013.
2.1.1. CKD. Patients were followed up in the Day Hospital-
Day Service of our Obstetrics Unit with a diagnosis of
CKDantedating pregnancy, hypertension, and/or proteinuria
>0.3 g/day. CKD was defined as “any anomaly of blood and
urine composition, or imaging or pathological data, lasting
for at least three months or a Glomerular Filtration Rate
(GFR) below 60mL/min for the same time period” [5]. GFR
was calculated by theCockroft-Gault andMDRD formulae or
by CKD-EPI formula on data collected within 3months prior
to conception. CKD-EPI was finally chosen for calculation
because of its wider diffusion in nephrology. When this
parameter was not available, serum creatinine measured
at first control during pregnancy was used, as previously
described [30, 31].
2.1.2. Preeclampsia. PE was defined as hypertension and
proteinuria >300mg/day occurring after the 20th gestational
week in a previously normotensive, nonproteinuric woman.
Both alterations should be reversible within 3 months from
delivery [1–3].
Patients with a clinical suspicion of PE were hospital-
ized in the Gynaecology and Obstetrics Unit; based on
the diagnostic criteria, diagnosis was completed only after
delivery, according to the criteria mentioned above. Patients
were stratified into confirmed PE or “Other” cases (isolated
pregnancy-induced hypertension, fetal growth restriction,
chronic hypertension, and isolated pregnancy-induced pro-
teinuria).
Exclusion criteria were twin pregnancies, congenital mal-
formations, chromosomal anomalies, or maternal diseases
other than CKD and hypertension.
Only patients who delivered a singleton and who had at
least one Doppler analysis and one assessment of sFlt-1/PlGF
ratio after the 20th gestational week were considered.
2.2. sFlt-1 and PlGF Assays. Two mL of venous blood were
collected from each patient and control using serological
vials without anticoagulant and gel. Serum was obtained by
centrifugation at 3000 rpm at 4∘C for 20 minutes within 3 h
from collection and stored at −80∘C until testing. All samples
were analyzed at the same time. sFlt-1 and PlGF serum
levels were determined in parallel by specific, commercially
available electrochemiluminescence immunoassays (Elecsys,
Roche, Penzberg, Germany) using a Cobas-e-411 immuno-
analyzer following the manufacturer’s instructions. The sFlt-
1 and PlGF serum levels of our control pregnancies were
comparable to those previously reported by Verlohren and
colleagues [24, 32].
When two or more samples were available, the first one
was chosen.
2.3. Doppler Flow Studies. The evaluation of uterine arteries
took into account the resistance index (RI) or Pourcelot ratio,
defined as peak systolic flow minus peak end diastolic flow
divided by peak systolic flow.
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Table 1: Main baseline data in the study group.
Data at referral or at 1st test
(median; min–max or %)
CKD
(𝑛: 35)
PE
(𝑛: 24)
Other
(𝑛: 17) Statistical significance
Age (yrs) 32 (19–41) 36.5 (19–54) 36 (28–46) 𝑃0 = 0.023
Nulliparous (%) 71.4% 75.0% 47.1% 𝑃0 = 0.131
BMI 22.6 (14.8–42.9) 24.9 (14.5–36.0) 27.3 (17.6–43.9) 𝑃0 = 0.154
Caucasians (%) 91.4% 95.8% 70.6% 𝑃0 = 0.034
Week of test 30 (21–39) 32 (26–36) 34 (25–39) 𝑃0 = 0.065
Hypertension (%) 34.3% 100% 100% 𝑃0 < 0.001
Proteinuria g/day 0.45 (0.04–3.4) 0.84 (0.3–16.2) 0.23 (0.06–3.7) 𝑃0 < 0.001
Proteinuria <0.3 (%) 40% — 64.7%
𝑃0 = 0.004
≥0.3–<0.5 g/day (%) 14.3% 29.2% 11.8%
0.5–1 g/day (%) 11.4% 25.0% 11.8%
1–3 g/day (%) 28.6% 29.2% 5.9%
≥3 g/day (%) 5.7% 16.7% 5.9%
s-Creatinine (mg/dL) 0.60 (0.38–2.59) 0.67 (0.44–0.99) 0.57 (0.34–0.83) 𝑃0 = 0.106
GFR (mL/min) 119 (23–147) 115 (48–144) 124 (91–138) 𝑃0 = 0.217
CKD: chronic kidney disease; PE: preeclampsia; BMI: body mass index; GFR: glomerular filtration rate (by CKD-EPI formula); 𝑃0: significance across groups;
𝑃1: CKD versus PE;𝑃2: CKD versus Other; 𝑃3: PE versus Other. Significance between groups: maternal age: 𝑃1 = 0.050; 𝑃2 = 0.011; 𝑃3 = 0.62; hypertension:
𝑃1 < 0.001; 𝑃2 < 0.001; proteinuria: 𝑃1 = 0.011; 𝑃2 = 0.165; 𝑃3 < 0.001; proteinuria (%): 𝑃1 = 0.006; 𝑃2 = 0.368; 𝑃3 < 0.001.
Note. Causes of CKD: glomerular 11; interstitial 13; single kidney 3; diabetic nephropathy 3; Other 5. Other diseases (differential diagnosis with PE) included
pregnancy-induced hypertension (6 cases); intrauterine growth restriction with or without hypertension (4); chronic hypertension (6 cases); HELLP syndrome
after delivery (1 case).
According to the literature, an abnormal uterine artery
Doppler FVW was defined as the mean (of the two uterine
arteries) resistance index (RI) of ≥0.58 [33].
Umbilical artery Doppler waveforms were analyzed using
the Pulsatility Index (PI), defined as peak systolic flowminus
end diastolic flow divided by mean flow. Normal PI values
were defined according to the gestational age-adjusted data
proposed by Guiot et al. [34].
2.4. Statistical Analysis. Besides uteroplacental flow mea-
surements and sFlt-1/PlGF ratio, the following clinical and
laboratory data were gathered: age, parity, race, week of tests,
24-hour proteinuria, serum creatinine, GFR, total serum
albumin, blood pressure and antihypertensive therapy, BMI,
gestational age at delivery, type of delivery, clinical compli-
cations in the mother, fetal weight percentile according to
the international birth weight references (InES charts [35]),
Apgar index, sex, admission to neonatal intensive care unit,
and outcome.
A descriptive analysis was performed as appropriate
(mean and standard deviation for parametric data and
median and range for nonparametric data, after checking
distribution by visual inspection and Shapiro-Wilk test, if
needed).
Comparisons among groups were done by ANOVA,
which, if significant, was followed by pairwise analysis using
the Bonferroni method. Kruskal-Wallis and Mann-Whitney
tests were used for nonparametric data. Pearson’s 𝜒2 was used
for categorical variables, after cross-tabulation.
The clinical diagnosis, according to the criteria men-
tioned above, was considered as the gold standard for refer-
ence.
The diagnostic yield of the sFlt-1/PlGF ratio was analysed
by ROC curve tracing, followed by Youden’s J statistics to
determine optimal cut-off values for the sFlt-1/PlGF ratio.
The diagnostic yield of the Doppler study was assessed
by sensitivity analysis. ROC curves were built considering
CKD versus conditions “other than CKD” (PE and other
hypertensive disorders or PE alone). The AUC built for the
two tests was compared by means of 𝑧 test according to
Henley and McNeil.
Significance was assumed when 𝑃 < 0.05, unless
dealing with multiple pairwise comparisons: in that case, the
significance limit was calculated according to Bonferroni.
3. Results
3.1. Clinical Data. Table 1 reports the main characteristics of
the study population, recruited from January to December
2013, as assessed at the beginning of pregnancy (age, BMI,
and parity) or at the time of testing (kidney function,
hypertension, and proteinuria).
From a clinical-biochemical point of view, there was,
as expected, a consistent overlap among the three groups.
This confirmed the impossibility to distinguish among these
conditions solely on the basis of kidney function assessment
or proteinuria.
Table 2 reports the main pregnancy-related outcomes
in the three groups. Patients with overt PE had a higher
incidence of preterm (<37 completed gestational weeks) and
early preterm (<34 completed gestational weeks) delivery,
lower birth weight, and severe growth restriction (higher
prevalence of babies below the 5th centile for gestational age).
In contrast, CKD patients, likely also as a reflection of the
selection that included many subjects with normal kidney
function and milder clinical anomalies, displayed the most
favourable outcomes, while the group defined as “Other”
showed an intermediate prognosis.
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Table 2: Main outcome data.
Data at delivery
(median; min–max or %)
CKD
(𝑛: 35)
PE
(𝑛: 24)
Other
(𝑛: 17) Statistical significance
Cesarean section (%) 34.3% 75% 76.5% 𝑃0 = 0.002
Gestational week 37 (30–40) 33 (27–38) 36 (33–39) 𝑃0 < 0.001
Preterm (<37 weeks) (%) 40.0% 87.5% 58.8% 𝑃0 = 0.001
Early preterm (<34 weeks) (%) 11.4% 54.2% 23.5% 𝑃0 = 0.001
Weight at birth (grams) 2679 ± 610 1713 ± 710 2341 ± 664 𝑃0 < 0.001
SGA <10% (INeS) (%) 5.7% 25.0% 29.4% 𝑃0 = 0.048
SGA <5% (INeS) (%) 5.7% 16.7% 11.8% 𝑃0 = 0.397
CKD: chronic kidney disease; PE: preeclampsia; SGA: small for gestational age baby, according to INeS charts. 𝑃0: significance across groups; 𝑃1: CKD versus
PE; 𝑃2: CKD versus Other; 𝑃3: PE versus Other.
Note. Significance among groups: cesarean section: 𝑃1 = 0.007; 𝑃2 = 0.010; 𝑃3 = 1.0; gestational week: 𝑃1 < 0.001; 𝑃2 = 0.161; 𝑃3 = 0.003; preterm <37
weeks: 𝑃1 = 0.001; 𝑃2 = 0.327; 𝑃3 = 0.063; early preterm: 𝑃1 = 0.001; 𝑃2 = 0.413; 𝑃3 = 0.101; weight at birth (Bonferroni’s Test): 𝑃1 < 0.001; 𝑃2 = 0.254;
𝑃3 = 0.010; SGA (<10∘): 𝑃1 = 0.053; 𝑃2 = 0.031; 𝑃3 = 1.0.
3.2. Molecular and Biophysical Biomarkers. Table 3 sum-
marizes biomarker distribution as considered in the three
subsets of patients. The test was performed a median of two
weeks earlier in CKD patients, as a reflection of the earlier
referral of women with known kidney disease.The difference
was not statistically significant (Table 1).
In all cases, the clinical definitionwas taken as a reference.
The lowest sFlt-1/PlGF ratio was detected in CKD
patients, while the highest was observed in PE patients on
account of the lower sFlt-1 and higher PlGF in the first subset
of cases.
The sFLt-1 levels (median: 1893 pg/mL) of CKD patients
were in line with the normal ranges for gestational age pro-
vided by the analytical kit (median: 1934 pg/mL). In contrast,
PlGF levels were somehow lower in CKD patients (median:
270 pg/mL) as compared to normal controls provided by the
company (median: 439 pg/mL).
Figure 1 shows the sFlt-1/PlGF ratio pattern in the three
subsets of patients, defined upon the reference clinical crite-
ria. PE patients show the highest ratio, with aminimal overlap
with CKD patients, while the “Other” diseases consistently
overlap with both PE and CKD. In line with normal placental
vascularization, the uteroplacental flow was significantly
better preserved in most CKD patients (85.7% normal flows,
with no case showing an impairment of both uterine and
umbilical Doppler indexes), in stark contrast to PE cases
in which only one-third of the subjects (37.5%) had normal
Doppler flow indexes at diagnosis. Again, the “other diseases”
pattern was intermediate (Table 3).
Taking the clinical diagnosis as reference, sensitivity,
specificity, and positive and negative predictive values of
Doppler study were calculated considering the presence of at
least one impaired uteroplacental flow as indicative for the
diagnosis of PE and “Other” diseases versus CKD: sensitivity
56.1% (95% CI: 39.7%–71.5%) and specificity 85.7% (95% CI:
69.7%–95.2%), with a positive predictive value of 82.1% (95%
CI: 63.1%–93.9%) and a negative predictive value of 62.5%
(95% CI: 47.4%–76.0%).
The diagnostic yield increases considering only the two
clinical subsets of PE and CKD: sensitivity 62.5% (95% CI:
40.6%–81.2%) and specificity 85.7% (95% CI: 69.7%–95.2%),
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Figure 1: sFlt-1/PlGF ratio distribution pattern in CKD (blue), PE
(red), and “other hypertensive disorders” (green) patients.
with a positive predictive value of 75% (95%CI: 50.9%–91.3%)
and a negative predictive value of 76.9% (95% CI: 60.7%–
88.9%).
3.3. ROC Analysis. The diagnostic potential of the sFlt-
1/PlGF ratio versus the clinical diagnosis of CKD or PE was
further assessed by ROC curves.
Figure 2 combines two ROC curves that were prepared
taking all cases into consideration (a) and by selecting only
the two best defined CKD and PE subsets (b). The ratio was
considered for the differential diagnosis between CKD and
PE or between CKD and PE plus “Other” diseases in both
populations: in other terms, the curves analyse the probability
of having a “disease other than CKD,” as clinically defined.
The area of the first curve (all cases: 76 observations) was
0.9031 (Figure 2).
The “best cut-point” identified by Youden’s J statistics was
at, or above, 32.81 (sensitivity 82.9%; specificity 91.4%; cor-
rectly classified: 86.8%). A specificity of 97.1% was obtained at
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Table 3: Molecular and biophysical biomarkers.
Biomarkers: median; min–max or % CKD(𝑛: 35)
PE
(𝑛: 24)
Other
(𝑛: 17) Statistical significance
sFlt-1 (pg/mL) 1893(585–13306)
11184
(308–28182)
5472
(222–15984) 𝑃0 < 0.001
PlGF (pg/mL) 270(11.5–1770)
39
(10.2–330.3)
94.4
(11.5–2564) 𝑃0 < 0.001
sFlt-1/PlGF ratio 8.29(1.04–137.40)
317.32
(28.05–2619.11)
58.96
(1.46–355.45) 𝑃0 < 0.001
Normal umbilical and uterine flow 85.7% 37.5% 52.9%
𝑃0 = 0.001Normal uterine or umbilical flow 14.3% 29.2% 29.4%
Abnormal umbilical and uterine flow 0% 33.3% 17.6%
𝑃0: CKD versus PE versus Other; 𝑃1: CKD versus PE; 𝑃2: CKD versus Other; 𝑃3: PE versus Other.
Note. Comparisons between groups: sFlt-1: 𝑃1 < 0.001; 𝑃2 = 0.004; 𝑃3 = 0.003. PlGF: 𝑃1 < 0.001; 𝑃2 = 0.002; 𝑃3 < 0.003. Ratio sFlt1-PlGF: 𝑃1 < 0.001;
𝑃2 = 0.001; 𝑃3 = 0.001; prevalence of normal flows: 𝑃1 < 0.001; 𝑃2 = 0.017; 𝑃3 = 0.508.
Presence of at least one impaired uteroplacental flow for diagnosis of PE and Other diseases versus CKD: sensitivity 56.1% (95% CI: 39.7%–71.5%); specificity
85.7% (95% CI: 69.7%–95.2%); PPV 82.1% (95% CI: 63.1%–93.9%); NPV value 62.5% (95% CI: 47.4%–76.0%).
PE only versus CKD: sensitivity 62.5% (95% CI: 40.6%–81.2%); specificity 85.7% (95% CI: 69.7%–95.2%); PPV 75% (95% CI: 50.9%–91.3%); NPV: 76.9% (95%
CI: 60.7%–88.9%).
0.0
0.2
0.5
0.7
1.0
Se
ns
ib
ili
ty
Area under ROC curve = 0.9031
0.2 0.5 0.7 1.00.0
1 − specificity
Cut-points:
32.81 (sensitivity 82.93%; specificity 91.43%)
78.75 (sensitivity 62.89%; specificity 97.14%)
142.21 (sensitivity 48.78%; specificity 100.00%)
(a)
Area under ROC curve = 0.981
0.0
0.2
0.5
0.7
1.0
Se
ns
ib
ili
ty
0.2 0.5 0.7 1.00.0
1 − specificity
Cut-points:
28.05 (sensitivity 100.00%; specificity 85.71%)
78.75 (sensitivity 87.50%; specificity 97.14%)
(b)
Figure 2: (a) ROC curve obtained considering all cases (𝑛 = 76); (b) ROC curve obtained by selecting only CKD and PE patients (𝑛 = 59)
and excluding the “Other” diseases.
a ratio of 78.75 (sensitivity 62.9%; specificity 97.1%; correctly
classified: 86.8%), while specificity reached 100% at or above a
ratio of 142.21 (sensitivity: 48.8%; specificity: 100%; correctly
classified: 72.4%).
The area under the second ROC curve increased to 0.9810
by selecting clinical criteria only CKD and PE patients (59
cases) and excluding the “Other” diseases. In this analysis,
two “best cut-points” may be identified by Youden’s J statis-
tics. The first one was at 28.05 (sensitivity 100%; specificity
85.7%; correctly classified: 91.5%), the second one, shared by
the first curve, at 78.75 (sensitivity 87.5%; specificity 97.1%;
correctly classified: 93.2%).
There was a very close, although incomplete, correlation
among flow patterns, sFlt-1, PlGF levels, and their ratio, as
shown in Table 4. The median ratio sFlt-1/PlGF was 9.94 in
cases with normal umbilical and uterine flows, 136.26 when
one arterial flowwas altered, and 407.68when both flowswere
impaired.
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Table 4: Relationship between uteroplacental flow and the analyzed biomarkers.
Normal umbilical and
uterine flow
(𝑛: 48)
Normal uterine or
umbilical flow
(𝑛: 17)
Abnormal umbilical and
uterine flow
(𝑛: 11)
Statistical significance
sFlt-1 median (min–max) 2107(308–16573)
8374
(222–25538)
16241
(2350–28182) 𝑃0 < 0.001
PlGF median (min–max) 195.25(10.98–2564.0)
42.77
(10.39–796.90)
41.07
(10.15–247.10) 𝑃0 < 0.001
Ratio median (min–max) 9.94(1.04–439.37)
136.26
(1.86–2457.94)
407.68
(9.51–2619.11) 𝑃0 < 0.001
𝑃0 = Kruskal Wallis; MannWhitney 𝑃1 = normal versus partially altered flow; 𝑃2 = normal versus altered flow; 𝑃3 = partially altered flow versus altered flow.
sFlt-1: 𝑃1 = 0.011; 𝑃2 < 0.001; 𝑃3 = 0.025. PlGF: 𝑃1 = 0.017; 𝑃2 < 0.001; 𝑃3 = 0.264. Ratio PlGF/sFlt-1: 𝑃1 = 0.003; 𝑃2 < 0.001; 𝑃3 = 0.025.
However, the range was wide in all subsets (normal flows:
min: 1.04; max: 439.37; both altered flows: min: 9.51; max:
2619.11), with consistent overlap (Table 4).
The accuracy of the ratio sFlt-1/PlGF in identifying
diseases other than PE and CKD is higher than that of the
flow patterns, the first allowing to correctly classify up to
93% of the cases (limiting the comparison to CKD versus PE,
cut-point at ratio 78.75), versus 76.2% in the case of altered
flow(s). The difference between the two AUCs (at least one
altered flow in the differential diagnosis between CKD and
PE: 0.7411 ± 0.0587, versus cut-point at ratio 78.75: 0.9232 ±
0.0373) is significant (𝑧 test according to Hanley andMcNeil:
𝑃 = 0.0088).
3.4. Relationship between Biomarkers and Outcome. Regard-
less of the clinical diagnosis (PE, CKD, or others), a higher
ratio and the presence of impaired uteroplacental flow
were significantly associated with preterm delivery and SGA
babies: the median sFlt-1/PlGF ratio was 9.07 (min 1.04; max
137.40) in the 31 patients who delivered at or after 37 weeks;
it was 28.59 (1.86–356.58) in the cases who delivered at 34–37
weeks and 376.21 for patients who delivered before 34 weeks,
once more with a very wide dispersion (min–max: 3.09–
2619.11) (𝑃 < 0.001). In line with these data, the median ratio
was significantly lower in pregnancies leading to appropriate
for gestational age babies (ratio AGA: 19.39 versus SGA:
137.40, 𝑃 = 0.017).
4. Discussion
The main result of our study is to suggest that the analysis
of sFlt-1 and PlGF may add useful information to the routine
clinical assessment of patients with proteinuria and hyperten-
sion occurring or first discovered in pregnancy. In this series,
an sFlt-1/PlGF ratio above 150 was not compatible with CKD
alone, while a ratio below 30 was almost pathognomonic of
CKD (Tables 3 and 4).
The study of uteroplacental flows, readily available for
a first “bedside” indication, has a good, but incomplete,
correlation, as witnessed by relatively low sensitivity and
specificity (Table 3).
The clinical definition of the three main subsets of
patients emerges as a crucial point: our data are in line with
the conclusion of a recent reappraisal of serum biomarkers
in “high-risk” pregnancies: “multiple pathogenic pathways
lead to the disease recognized clinically as preeclampsia” [27].
The higher precision of ROC curves obtained by including
only the cases with a clear clinical diagnosis of PE and CKD,
omitting “Other” diseases, emphasizes the importance of a
careful clinical characterization.This observation clarifies the
difference between the present prospective and the previous
retrospective study, in which we excluded the uncertain cases
or “Other” diseases considered in the differential diagnosis of
PE. While the present study confirms CKD in the previously
reported range (ratio below 150), we found higher data
variability and a partial overlap between CKD, PE, and
“Other” diseases, leading to the suggestion of lowering the
discrimination cut-point (Figures 1 and 2).
For the first time to our knowledge, we carried out
a prospective attempt to perform differential diagnosis
between PE and CKD in pregnancy. The proposed use is to
support diagnosis in a setting in which a disease is already
present, hence beyond the clinical and ethical limits of
“uncertain prediction” in forecasting PE. On the contrary,
indication from biomarker analysis may have an immediate
clinical implication, since the management of CKD and PE
patients may not be the same [30, 31]. However, there are
someweaknesses in the present study thatmay lead to further
future analyses. First of all, the study population size is
small. Moreover, we did not repeat samples for most of the
patients, and in particular for those with PE. In fact, PE
patients were usually referred to our tertiary care center in
presence of a full-blown clinical picture and usually required
rapid delivery. A further limit is represented by the different
gestational age at testing, which was lower in CKD mothers,
albeit not significantly. Normalization for gestational age
should be considered in larger series.
Furthermore, no CKD patient included in our study had
the clinical hallmarks of PE superimposed on CKD. Hence,
the present study is not able to give insights on this situation,
of great potential interest, that should be analysed by means
of large, multicentre studies, on prospectively followed CKD
patients.
The working hypothesis of our study was that the patho-
genesis of proteinuria and hypertension, occurring or wors-
ening in pregnancy in CKD patients, differed from the same
signs and symptoms occurring in PE. The “CKD placenta”
was expected to develop normally, thus leading to a normal
Disease Markers 7
angiogenic/antiangiogenic balance and to normal uteropla-
cental flows. The use we propose for the sFlt-1/PlGF ratio
herein differs from its original indication.Thismolecular tool
was developed in order to predict PE onset in low-risk and
high-risk women, a controversial issue due to the imperfect
prognostic power and to the risk of clinical interference with
the delicatemanagement of high-risk pregnancies [27–29, 36,
37]. Some authors maintain that PE is a self-evident disease
and that there is no need for further diagnostic tools. This
is probably true in most cases in which prepregnancy data
are available. However, the clinical definition cannot cover
at least three specific situations involved in the differential
diagnosis with CKD. The first one is the lack of data before
pregnancy or within the first twenty weeks of gestation: since
kidney diseases are frequently asymptomatic, the lack of data
hinders differential diagnosis [16, 30, 31]. In our experience,
CKD is diagnosed, first encountered, or recognised in its
potential clinical importance in over one-third of the cases
during pregnancy [30].
The second situation is the onset of a kidney disease
during pregnancy. There is no way to differentiate a newly
occurring glomerulonephritis from PE by using routine
clinical or laboratory tools.This is also true for the third point:
the flare during pregnancy of a known glomerulonephritis or
immunologic disease that was previously in remission (e.g.,
systemic lupus erythematosus).
5. Conclusions
The differential diagnosis between CKD during pregnancy
and PE may be supported both by the analysis of uteropla-
cental flows and by the analysis of sFlt-1, PlGF, and their ratio.
While the flow analysis may be of immediate help, due to the
wide bedside availability, there is a major role for sFlt-1 and
PlGF in supporting the differential diagnosis.
The data described in this paper may lead to practical
clinical suggestions: in pregnancy, the identification of CKD
patients may support a more expectant management, while
the finding of impaired flows and high ratio may suggest
stricter follow-up and support earlier delivery.
After pregnancy, the patients identified with CKD may
receive timely care; furthermore, we suggest that particular
attention should be posed to the PE cases with low sFlt-
1/PlGF ratio and/or normal uteroplacental flows, in order
to highlight associated or predisposing diseases that may be
more common in this subset of “atypical” cases.
Furthermore, kidney function assessment is not included
in the routine work-up of pregnant women according to the
main current pregnancy management guidelines, including
the Italian ones and the well-known NICE ones [38, 39].
We hope that the growing interest on CKD and pregnancy
may help in changing this attitude, leading to the addition
of a basic evaluation of the kidney function in all pregnant
women.
Further studies are required to refine our findings on a
larger scale and to get new physiological insights into the
development of proteinuria and hypertension in pregnancy.
The issue of PE superimposed on CKD is of great clinical
interest. To analyse this rare situation, we need to set large
multicentre studies, prospectively following the patients with
repeated sFlt-1 and PlGFmeasurements since the early stages
of pregnancy. The promising results obtained in our series
may increase interest and make such analyses possible in the
future.
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